To simplify use of these four established FSHD biomarkers that have now been evaluated over nine independent FSHD transcriptomic data sets (with PAX7 target gene repression the only biomarker achieving significance on 9/9 data sets), we have written a code for evaluating the PAX7 target gene repression biomarker and each of the three DUX4 target gene expression biomarkers (Supplementary Material, File S1). The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.